Parker A.L.,University of Cardiff |
Bradshaw A.C.,British Heart Foundation Glasgow Cardiovascular Research |
Alba R.,British Heart Foundation Glasgow Cardiovascular Research |
Alba R.,Nanotherapix S.L |
And 3 more authors.
Methods in Molecular Biology | Year: 2014
Adenoviral vectors hold immense potential for a wide variety of gene therapy based applications; however, their efficacy and toxicity is dictated by "off target" interactions that preclude cell specific targeting to sites of disease. A number of "off target" interactions have been described in the literature that occur between the three major capsid proteins (hexon, penton, and fiber) and components of the circulatory system, including cells such as erythrocytes, white blood cells, and platelets, as well as circulatory proteins including complement proteins, coagulation factors, von Willebrand Factor, p-selectin as well as neutralizing antibodies. Thus, to improve efficacious targeting to sites of disease and limit nonspecific uptake of virus to non-target tissues, specifically the liver and the spleen, it is necessary to develop suitable strategies for genetically modifying the capsid proteins to preclude these interactions. To this end we have developed versatile systems based on homologous recombination for modification of each of the major capsid proteins, which are described herein. © 2014 Springer Science+Business Media, LLC.